1.32
price up icon3.94%   0.05
pre-market  プレマーケット:  1.33   0.01   +0.76%
loading
前日終値:
$1.27
開ける:
$1.29
24時間の取引高:
998.84K
Relative Volume:
0.33
時価総額:
$150.34M
収益:
$13.45M
当期純損益:
$-178.23M
株価収益率:
-0.80
EPS:
-1.65
ネットキャッシュフロー:
$-132.53M
1週間 パフォーマンス:
+5.18%
1か月 パフォーマンス:
-21.43%
6か月 パフォーマンス:
-69.09%
1年 パフォーマンス:
-70.86%
1日の値動き範囲:
Value
$1.27
$1.35
1週間の範囲:
Value
$1.22
$1.36
52週間の値動き範囲:
Value
$1.04
$8.83

Fate Therapeutics Inc Stock (FATE) Company Profile

Name
名前
Fate Therapeutics Inc
Name
セクター
Healthcare (1176)
Name
電話
858.875.1803
Name
住所
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Name
職員
181
Name
Twitter
@fatethx
Name
次回の収益日
2024-11-06
Name
最新のSEC提出書
Name
FATE's Discussions on Twitter

FATE を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
FATE
Fate Therapeutics Inc
1.32 150.34M 13.45M -178.23M -132.53M -1.65
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
427.89 110.19B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
687.80 75.58B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
647.39 38.71B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
264.99 34.18B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
117.25 28.11B 3.30B -501.07M 1.03B -2.1146

Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-11-18 アップグレード BofA Securities Underperform → Neutral
2024-06-17 アップグレード Piper Sandler Neutral → Overweight
2023-03-27 再開されました Wells Fargo Equal Weight
2023-01-24 ダウングレード H.C. Wainwright Buy → Neutral
2023-01-06 ダウングレード BMO Capital Markets Outperform → Market Perform
2023-01-06 ダウングレード BofA Securities Buy → Underperform
2023-01-06 ダウングレード Cowen Outperform → Market Perform
2023-01-06 ダウングレード Piper Sandler Overweight → Neutral
2023-01-06 ダウングレード Stifel Buy → Hold
2023-01-06 ダウングレード Truist Buy → Hold
2023-01-06 ダウングレード Wedbush Outperform → Neutral
2023-01-03 ダウングレード Guggenheim Buy → Neutral
2022-12-22 ダウングレード Oppenheimer Outperform → Perform
2022-12-15 開始されました Goldman Sell
2022-11-04 再開されました Cantor Fitzgerald Overweight
2022-10-10 開始されました Canaccord Genuity Buy
2022-08-18 再開されました Wells Fargo Overweight
2022-07-28 開始されました Needham Hold
2022-07-11 アップグレード BMO Capital Markets Market Perform → Outperform
2022-06-03 開始されました Robert W. Baird Neutral
2022-02-11 再開されました BMO Capital Markets Market Perform
2021-12-15 アップグレード Wedbush Neutral → Outperform
2021-12-07 開始されました Cowen Outperform
2021-11-09 アップグレード Citigroup Neutral → Buy
2021-08-26 開始されました Morgan Stanley Equal-Weight
2021-06-07 アップグレード H.C. Wainwright Neutral → Buy
2021-05-07 アップグレード Wedbush Neutral → Outperform
2021-04-26 再開されました Jefferies Buy
2021-02-26 開始されました BofA Securities Buy
2021-02-26 ダウングレード Wedbush Outperform → Neutral
2021-02-11 ダウングレード Citigroup Buy → Neutral
2021-01-27 再開されました H.C. Wainwright Neutral
2020-05-13 開始されました H.C. Wainwright Buy
2020-03-04 開始されました Barclays Overweight
2020-01-09 ダウングレード BMO Capital Markets Outperform → Market Perform
2019-12-30 繰り返されました Mizuho Buy
2019-12-09 アップグレード Wells Fargo Market Perform → Outperform
2019-11-12 開始されました SunTrust Buy
2019-11-06 ダウングレード Wells Fargo Outperform → Market Perform
2019-10-01 開始されました Stifel Buy
2019-08-09 開始されました BTIG Research Buy
2019-07-22 開始されました Cantor Fitzgerald Overweight
2019-07-12 開始されました Oppenheimer Outperform
2019-06-13 開始されました Mizuho Buy
2019-06-07 開始されました ROTH Capital Neutral
2019-05-31 開始されました Guggenheim Buy
2019-05-24 再開されました Citigroup Buy
2019-03-28 開始されました SVB Leerink Outperform
2019-01-03 ダウングレード Stephens Overweight → Equal-Weight
2018-11-05 開始されました Jefferies Buy
2018-08-01 開始されました Citigroup Buy
2018-03-06 ダウングレード H.C. Wainwright Buy → Neutral
すべてを表示

Fate Therapeutics Inc (FATE) 最新ニュース

pulisher
07:22 AM

Equities Analysts Offer Predictions for FATE FY2025 Earnings - MarketBeat

07:22 AM
pulisher
03:00 AM

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Recommendation of “Hold” by Brokerages - Defense World

03:00 AM
pulisher
Jan 19, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Short Interest Update - MarketBeat

Jan 19, 2025
pulisher
Jan 16, 2025

JPMorgan Chase & Co. Has $6.43 Million Stake in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jan 16, 2025
pulisher
Jan 16, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Bought by JPMorgan Chase & Co. - MarketBeat

Jan 16, 2025
pulisher
Jan 15, 2025

Day 5 of Loss Streak for Fate Therapeutics Stock with -33% Return (vs. -24% YTD) [1/15/2025] - Trefis

Jan 15, 2025
pulisher
Jan 14, 2025

Fate Therapeutics' SWOT analysis: stock poised for growth amid clinical progress - Investing.com

Jan 14, 2025
pulisher
Jan 13, 2025

Fate Therapeutics’ chief legal officer Cindy Tahl sells $8,763 in stock - Investing.com Nigeria

Jan 13, 2025
pulisher
Jan 13, 2025

Fate Therapeutics CEO sells shares worth $13,405 By Investing.com - Investing.com Canada

Jan 13, 2025
pulisher
Jan 13, 2025

Fate Therapeutics' chief legal officer Cindy Tahl sells $8,763 in stock By Investing.com - Investing.com South Africa

Jan 13, 2025
pulisher
Jan 13, 2025

Fate Therapeutics executive sells $9,269 in common stock By Investing.com - Investing.com Canada

Jan 13, 2025
pulisher
Jan 13, 2025

Fate Therapeutics' chief legal officer Cindy Tahl sells $8,763 in stock - Investing.com Canada

Jan 13, 2025
pulisher
Jan 13, 2025

Insider Selling: Fate Therapeutics, Inc. (NASDAQ:FATE) CEO Sells $13,405.70 in Stock - MarketBeat

Jan 13, 2025
pulisher
Jan 13, 2025

Barclays PLC Has $1.49 Million Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jan 13, 2025
pulisher
Jan 07, 2025

Fate Therapeutics, Inc. Announces Retirement of J. Scott Wolchko as Treasurer, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer - Marketscreener.com

Jan 07, 2025
pulisher
Jan 07, 2025

Fate Therapeutics appoints new CEO, enters advisory pact By Investing.com - Investing.com Canada

Jan 07, 2025
pulisher
Jan 06, 2025

Fate Therapeutics appoints new CEO, enters advisory pact - Investing.com

Jan 06, 2025
pulisher
Jan 06, 2025

Jane Street Group LLC Sells 69,867 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jan 06, 2025
pulisher
Jan 03, 2025

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jan 03, 2025
pulisher
Jan 03, 2025

Geode Capital Management LLC Acquires 10,863 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jan 03, 2025
pulisher
Dec 31, 2024

Stifel Financial Corp Sells 17,391 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Dec 31, 2024
pulisher
Dec 31, 2024

Franklin Resources Inc. Cuts Stake in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Dec 31, 2024
pulisher
Dec 29, 2024

Barclays PLC Buys 301,389 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Dec 29, 2024
pulisher
Dec 28, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Recommendation of “Hold” from Analysts - Defense World

Dec 28, 2024
pulisher
Dec 28, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives $6.75 Average Target Price from Brokerages - MarketBeat

Dec 28, 2024
pulisher
Dec 27, 2024

Redmile Group, LLC Reduces Stake in Fate Therapeutics Inc - GuruFocus.com

Dec 27, 2024
pulisher
Dec 26, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Director Acquires $668,579.52 in Stock - MarketBeat

Dec 26, 2024
pulisher
Dec 26, 2024

Redmile group sells $573,943 in Fate Therapeutics stock By Investing.com - Investing.com South Africa

Dec 26, 2024
pulisher
Dec 26, 2024

Redmile group sells $573,943 in Fate Therapeutics stock - Investing.com

Dec 26, 2024
pulisher
Dec 24, 2024

State Street Corp Sells 85,715 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Dec 24, 2024
pulisher
Dec 24, 2024

Fate Therapeutics stock hits 52-week low at $1.59 By Investing.com - Investing.com Canada

Dec 24, 2024
pulisher
Dec 21, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $497,000 Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Dec 21, 2024
pulisher
Dec 19, 2024

Critical Survey: Fate Therapeutics (NASDAQ:FATE) versus HilleVax (NASDAQ:HLVX) - Defense World

Dec 19, 2024
pulisher
Dec 18, 2024

Fmr LLC Buys 46,892 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Dec 18, 2024
pulisher
Dec 17, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Sees Significant Growth in Short Interest - MarketBeat

Dec 17, 2024
pulisher
Dec 16, 2024

FATE LAWSUIT ALERT: Levi & Korsinsky Notifies Fate Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - Marketscreener.com

Dec 16, 2024
pulisher
Dec 16, 2024

Charles Schwab Investment Management Inc. Has $2.67 Million Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Dec 16, 2024
pulisher
Dec 15, 2024

Fate Therapeutics' SWOT analysis: cell therapy stock shows promise amid risks - Investing.com

Dec 15, 2024
pulisher
Dec 15, 2024

Fate Therapeutics' SWOT analysis: cell therapy stock shows promise amid risks By Investing.com - Investing.com South Africa

Dec 15, 2024
pulisher
Dec 13, 2024

BNP Paribas Financial Markets Raises Stake in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Dec 13, 2024
pulisher
Dec 12, 2024

Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Dec 12, 2024
pulisher
Dec 12, 2024

FATE stock touches 52-week low at $1.96 amid market challenges - Investing.com

Dec 12, 2024
pulisher
Dec 12, 2024

FATE stock touches 52-week low at $1.96 amid market challenges By Investing.com - Investing.com South Africa

Dec 12, 2024
pulisher
Dec 10, 2024

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus - The Manila Times

Dec 10, 2024
pulisher
Dec 09, 2024

Fate Therapeutics Presents New Phase 1 Clinical Data of - GlobeNewswire

Dec 09, 2024
pulisher
Dec 09, 2024

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for - EIN News

Dec 09, 2024

Fate Therapeutics Inc (FATE) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$21.80
price up icon 4.81%
$73.47
price up icon 2.14%
$22.10
price up icon 16.13%
$367.97
price up icon 2.52%
biotechnology ONC
$218.70
price up icon 4.10%
$117.25
price up icon 4.75%
大文字化:     |  ボリューム (24 時間):